Open AccessEfficacy and Safety of Canagliflozin in Patients with Type 2 Diabetes and Stage 3 Nephropathy
Author(s) -
Hala Yamout,
Vlado Perkovic,
Melanie J. Davies,
Vincent Woo,
Dick de Zeeuw,
Cristiana Mayer,
Ujjwala Vijapurkar,
Irina Kline,
Keith Usiskin,
Gary Meininger,
George L. Bakris
Publication year - 2014
Publication title -
american journal of nephrology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.394
H-Index - 85
eISSN - 1421-9670
pISSN - 0250-8095
DOI - 10.1159/000364909
Subject(s) - canagliflozin , medicine , kidney disease , renal function , placebo , type 2 diabetes , blood pressure , diabetes mellitus , diabetic nephropathy , urology , population , gastroenterology , endocrinology , pathology , alternative medicine , environmental health
Some sodium glucose co-transporter 2 (SGLT2) inhibitors are approved for the treatment of patients with type 2 diabetes mellitus (T2DM) with an estimated glomerular filtration rate (eGFR) of ≥45 ml/min/1.73 m(2). The efficacy and safety of canagliflozin, an approved SGLT2 inhibitor, was evaluated in patients with stage 3 chronic kidney disease (CKD; eGFR ≥30 to <60 ml/min/1.73 m(2)).
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom